An observational study in Prostate Cancer (Diagnosis), Bone Metastasis and PSMA PET, sponsored by Xijing Hospital. Recruiting at 9 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Xijing Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by Xijing Hospital — 10 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · Xijing Hospital.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 6th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →10 of the 10 studies in Prostatic Neoplasms by Xijing Hospital are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18–100 · Men only
Xijing Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Xijing Hospital · Sites in China
Ages 18–75 · Men only
Xijing Hospital · Sites in China
Ages 40–90 · Men only · Healthy volunteers
Xijing Hospital · Sites in United States, China
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 190 across the 4 interventional studies, 1,000 across the 6 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
4 of the studies in Prostatic Neoplasms by Xijing Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06604130Xijing HospitalPlasma Exosome RNA to Diagnose Prostate Cancer | 2026-12-31 |
| NCT07492927Xijing HospitalPlasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer | 2026-12-31 |
| NCT06914427Xijing HospitalPET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique | 2027-03-01 |
| NCT07553754Xijing HospitalPlasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summary:
This prospective, multicenter study aims to discover, develop, and validate a plasma exosomal RNA-based signature as a rule-out test for predicting bone metastasis in prostate cancer, using baseline treatment-naïve PSMA PET as the gold standard. The study is designed in four sequential phases:
Phase 1 (Discovery, n=250): High-throughput sequencing of plasma exosomal RNAs to identify differentially expressed candidate RNAs.
Phase 2 (Model Development, n=300): Digital droplet PCR (ddPCR) analysis of candidates in an independent cohort to construct and lock the final multi-RNA predictive signature using appropriate machine learning methods.
Phase 3 (Internal Validation, n=300): Independent validation of the locked signature in a consecutive cohort reflecting natural disease prevalence.
Phase 4 (External Validation, n=150): Final independent validation in a multi-center cohort enriched for bone metastasis.
Primary Outcome:
To evaluate the diagnostic performance of the signature as a rule-out test for PSMA PET-defined bone metastasis. The primary performance metrics are:
Sensitivity, with a prespecified target of ≥95% (to ensure minimal false negatives).
Specificity at the threshold that achieves the ≥95% sensitivity. A specificity of ≥30% will be considered supportive of clinical utility. A specificity of ≥30% (or a lower bound of the 95% confidence interval exceeding 20%) will be considered supportive of clinical utility.
Need:
Current biomarkers lack sensitivity and specificity for early detection of bone metastasis. More importantly, existing tools lack adequate negative predictive value to safely rule out bone metastasis in low-risk patients, leading to over-imaging or delayed detection. There is an urgent need for a non-invasive rule-out test to safely defer PSMA PET/CT in very-low-risk patients. Plasma exosomal RNAs offer a promising liquid biopsy approach, but prospective multicenter studies with rigorous validation are lacking.
Secondary Outcomes:
Inclusion Criteria:
Exclusion Criteria:
Background Prostate cancer (PCa) is a leading cause of cancer-related morbidity worldwide, with bone metastasis being the most frequent and devastating complication. Early and accurate detection of bone metastasis is critical for timely intervention and improved patient outcomes. However, current biomarkers such as PSA lack sufficient sensitivity and specificity for early metastasis detection, and conventional imaging (e.g., bone scan, CT) often identifies metastases only after they become clinically apparent. PSMA PET has emerged as the most sensitive imaging modality for defining metastatic status at baseline, but its high cost, limited availability, and radiation exposure preclude its use as a universal screening tool.
Concurrently, liquid biopsy-particularly the analysis of plasma exosomal RNAs-offers a unique window into tumor biology. Exosomal RNAs are stable in circulation, reflect the molecular characteristics of the primary tumor, and can be detected using sensitive methods such as high-throughput sequencing and digital droplet PCR. Despite their promise, large-scale prospective multicenter studies with rigorous multi-phase validation are lacking.
Need There is a critical unmet need for a non-invasive, robust biomarker that can identify patients at very low risk of bone metastasis, thereby allowing safe deferral of PSMA PET/CT. Existing tools lack adequate negative predictive value to confidently rule out bone metastasis in low-risk populations. A successful rule-out test would reduce unnecessary imaging, lower healthcare costs, and minimize patient radiation exposure. This study implements a four-stage design with phase-specific sample size considerations aligned with contemporary standards for biomarker development.
Study Design and Technical Phases This is a prospective, multicenter, phase-sequential biomarker development and validation study. The gold standard for bone metastasis status is baseline, treatment-naïve PSMA PET/CT. All blood samples are collected prior to any prostate cancer-related treatment and prior to prostate biopsy (if performed) to avoid biopsy-induced contamination. Whole blood (approximately 10 mL in EDTA tubes) is processed within 2 hours to obtain plasma, which is stored at -80°C until analysis.
The four phases are defined as:
Phase 1 (Discovery, n=250): High-throughput RNA sequencing (e.g., small RNA-seq) of plasma exosomes. Differential expression analysis (e.g., DESeq2 or edgeR) identifies candidate RNAs distinguishing patients with versus without bone metastasis. Multiple testing correction (FDR \<0.05) is applied.
Phase 2 (Model Development, n=300): An independent cohort enriched for bone metastasis (approximately 200 positive, 100 negative) is used for quantitative measurement of candidate RNAs using ddPCR. A continuous risk-scoring model is constructed using machine learning (e.g., regularized regression, random forests, or gradient boosting). The model is locked after internal cross-validation, before any validation data are examined.
Phase 3 (Internal Validation, n=300): A consecutive cohort reflecting natural disease prevalence (expected bone metastasis rate \~30%) is used to evaluate the locked model. In this phase, a single cut-off value is selected to achieve a sensitivity of ≥95%. The specificity at that cut-off is the primary endpoint. Secondary metrics (NPV, PPV, AUC, calibration, decision curve analysis) are also assessed.
Phase 4 (External Validation, n=150): A geographically distinct, multi-center cohort enriched for bone metastasis is used to assess generalizability, applying the same cut-off determined in Phase 3.
Statistical Considerations Sample Size Justification Sample sizes were chosen based on published recommendations for phased biomarker studies and on formal precision analysis for the primary endpoint (specificity at the ≥95% sensitivity threshold).
Phase 1 (Discovery, n=250): This sample size is typical for high-throughput discovery studies. With an expected bone metastasis prevalence of \~30%, approximately 75 positive and 175 negative cases will be available, providing sufficient power to detect differential expression with FDR \<0.05.
Phase 2 (Model Development, n=300): Following the "events per variable" (EPV) rule (≥10 events per candidate predictor) and assuming a parsimonious final model (≤20 candidate RNAs after Phase 1), a minimum of 200 positive events is required. The cohort is enriched for bone metastasis (target \~67% positive), thus a total of 300 patients (≈200 positive, ≈100 negative) is planned.
Phase 3 (Internal Validation, n=300): The primary endpoint is specificity at the cut-off achieving ≥95% sensitivity. Assuming a true specificity of 35% at this threshold, a sample of approximately 210 negative patients (from total n=300 with \~30% bone metastasis prevalence) yields a 95% confidence interval half-width of approximately ±6-7%. This precision is more than sufficient to rule out a clinically useless specificity (e.g., \<15%) and allows robust subgroup analyses.
Phase 4 (External Validation, n=150): This multi-center cohort is enriched for bone metastasis (target \~40-50% positive). The sample size of 150 (≈75 positive, ≈75 negative) allows precise estimation of specificity (95% CI half-width ±11% assuming 35% specificity) and sensitivity in an independent setting, confirming generalizability.
All sample sizes may be adjusted modestly based on actual recruitment; any adjustments will be documented.
Statistical Analysis Plan (High-Level) Analyses will be performed using R (version ≥4.2). The final analysis plan will be finalized before locking validation data.
Phase 1: Differential expression analysis (DESeq2/edgeR). Candidate selection based on fold change, adjusted p-value, and abundance.
Phase 2: Machine learning model building using cross-validation. The final continuous model is locked.
Phase 3: Apply the locked model to the internal validation cohort. Determine the cut-off value that achieves sensitivity ≥95%. Report specificity, NPV, PPV, AUC, calibration, and decision curve analysis at this cut-off.
Phase 4: Apply the same cut-off to the external validation cohort and repeat the performance evaluation.
Secondary/exploratory analyses: Correlation, subgroup analyses, mechanistic studies (as detailed in the secondary outcome measures).
Data Management Data will be stored centrally in a REDCap database with 3-step authentication. Data entry will occur approximately every 3-6 months. Patient confidentiality will be maintained.
The study enrolls a total of approximately 1000 patients with histologically confirmed prostate cancer from multiple centers. All patients undergo baseline PSMA PET/CT and provide pre-treatment blood samples (collected before any therapy and before prostate biopsy). The single overall cohort is allocated into four sequential, independent phases: Phase 1 (Discovery, n=250), Phase 2 (Model Development, n≥300, bone-metastasis enriched), Phase 3 (Internal Validation, n≥300, natural prevalence), and Phase 4 (External Validation, n=150, multi-center enriched). Bone metastasis status is defined by PSMA PET/CT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who provide blood samples for plasma exosomal RNA analysis collected prior to any treatment AND prior to prostate (if applicable).
Whole blood samples (approximately 10 mL) will be collected in EDTA tubes at this specified time point. Samples will be processed within 2 hours to obtain plasma and stored at -80°C until analysis.This timing ensures circulating exosomal RNA profiles reflect tumor biology without biopsy-induced contamination.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single cohort of 1000 patients with suspected or histologically confirmed prostate cancer who undergo baseline treatment-naïve PSMA PET imaging. All patients provide blood samples for plasma exosomal RNA analysis, collected prior to any treatment and prior to prostate biopsy. This cohort is used for a four-phase biomarker study: Phase 1 (Discovery, n=250) for RNA sequencing to identify candidate biomarkers; Phase 2 (Model Development, n=300) for digital PCR-based signature development; Phase 3 (Internal Validation, n=300) for independent validation in a consecutive cohort; and Phase 4 (External Validation, n=150) for multi-center validation. Bone metastasis status is defined by PSMA PET. Phase 2 and Phase 3 cohorts are temporally and geographically independent. No patient is included in more than one phase
Specificity of the plasma exosomal RNA-based predictive signature for detecting PSMA PET-defined bone metastasis at a prespecified sensitivity threshold of ≥95%
Description: The signature will be developed as a continuous risk score using machine learning in an independent development cohort (Phase 2, n≥300, enriched for bone metastasis). After locking the model, a single cut-off value will be selected in the internal validation cohort (Phase 3, n≥300, reflecting natural disease prevalence) to achieve a sensitivity of ≥95% for detecting PSMA PET/CT-defined bone metastasis. The primary outcome is the specificity of the signature at that cut-off. A specificity of ≥30% (or a lower bound of the 95% confidence interval exceeding 20%) will be considered supportive of clinical utility. Measurement tools and units: Plasma exosomal RNA level: digital droplet PCR (ddPCR), expressed as absolute copy number per mL of plasma. Bone metastasis status: PSMA PET/CT, binary (positive/negative). Sensitivity and specificity: proportions with 95% confidence intervals (Clopper-Pearson exact method).
Time frame: Baseline
Correlation between plasma exosomal RNA level and bone metastatic lesion count on PSMA PET
The number of bone metastatic lesions will be quantified by PSMA PET/CT as a discrete count. The Spearman rank correlation coefficient (rho) will be calculated to assess the monotonic association with exosomal RNA level.
Time frame: Baseline
Correlation between plasma exosomal RNA level and serum PSA level
Serum PSA will be measured in ng/mL using standard clinical laboratory methods. Spearman correlation coefficient will be calculated.
Time frame: Baseline
Correlation between plasma exosomal RNA level and PSMA PET SUVmax
SUVmax (maximum standardized uptake value) will be derived from PSMA PET/CT. Spearman correlation coefficient will be calculated.
Time frame: Baseline
Association between exo-RNA and MRI findings (exploratory)
MRI findings will be categorized asPI-RADs scores, "suspicious for bone metastasis" or "not suspicious".
Time frame: Baseline
Correlation between tissue RNA expression (RNA-seq, normalized counts like FPKM/TPM) and plasma exosomal RNA level (ddPCR, copies/mL)
In patients with available formalin-fixed paraffin-embedded (FFPE) or fresh frozen tumor tissue samples, RNA expression of the selected exosomal RNA candidates (e.g., the top 2-3 most differentially expressed RNAs from the locked signature) will be measured by RNA sequencing (RNA-seq). Expression levels will be quantified as normalized counts (e.g., fragments per kilobase of transcript per million mapped reads \[FPKM\] or transcripts per million \[TPM\]) using standard bioinformatics pipelines (e.g., STAR + featureCounts + DESeq2 normalization). The corresponding plasma exosomal RNA level of the same candidate is measured by digital droplet PCR (ddPCR) and expressed as absolute copy number per mL of plasma. The Spearman rank correlation coefficient (rho) and its 95% confidence interval will be calculated to assess the strength of association between tissue and plasma levels.
Time frame: Baseline
Mechanistic exploration of key driver candidates via functional assays (exploratory)
For the most significantly dysregulated RNA candidate(s) from the validated signature, functional assays will be performed: Cell proliferation: CCK-8 assay measured as absorbance at 450 nm, or EdU assay measured as percentage of EdU-positive cells. Cell migration/invasion: Transwell assay measured as number of migrated/invaded cells per high-power field (average of 5 fields). In vivo tumor growth: tumor volume measured by caliper in mm³ using formula (length × width²)/2. In vivo metastasis: number of macroscopic metastatic nodules counted. Descriptive statistics (mean ± SD, median with IQR) will be reported.
Time frame: Baseline
Subgroup analyses of diagnostic performance (exploratory)
The locked signature's performance (sensitivity, specificity, negative predictive value, positive predictive value) will be calculated separately for: Hormone-sensitive vs. castration-resistant prostate cancer Oligometastatic (≤3 lesions) vs. polymetastatic (\>3 lesions) disease Gleason grade group ≤7 vs. ≥8 Each performance metric will be reported with 95% confidence intervals.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 15 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.